ArticleJournal for immunotherapy of cancer2026

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

Aung Naing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.